Shanghai Kaibao Pharmaceutical Working Capital to Net Assets Ratio
Shanghai Kaibao Pharmaceutical working capital to net assets ratio. Shanghai Kaibao Pharmaceutical (300039) has a Working Capital to Net Assets ratio of 40.0% as of June 2026. Working capital of CN¥1.71 Billion (current assets of CN¥1.85 Billion minus current liabilities of CN¥138.51 Million) is measured against net assets of CN¥4.29 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check Shanghai Kaibao Pharmaceutical tangible equity quality to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Shanghai Kaibao Pharmaceutical (2006–2025)
Working capital to net assets ratio of Shanghai Kaibao Pharmaceutical from 2006 to 2025. This chart shows how Shanghai Kaibao Pharmaceutical's Working Capital to Net Assets ratio has evolved across 20 annual periods from 2006 to 2025. As of June 2026, the ratio stands at 40.0%, reflecting working capital of CN¥1.71 Billion against net assets of CN¥4.29 Billion CNY. See operational self-sufficiency of Shanghai Kaibao Pharmaceutical to measure how many days the company can operate on defensive assets alone.
Shanghai Kaibao Pharmaceutical Working Capital to Net Assets Ratio by Year (2006–2025)
Shanghai Kaibao Pharmaceutical working capital to net assets ratio by year from 2006 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Shanghai Kaibao Pharmaceutical from 2006 to 2025, covering 20 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see how large is Shanghai Kaibao Pharmaceutical's balance sheet.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 46.9% | CN¥2.07 Billion | CN¥4.42 Billion | CN¥2.24 Billion | CN¥166.91 Million | ▼ -6.3 pp |
| 2024 | 53.2% | CN¥2.18 Billion | CN¥4.10 Billion | CN¥2.42 Billion | CN¥232.30 Million | ▲ +24.9 pp |
| 2023 | 28.3% | CN¥1.14 Billion | CN¥4.03 Billion | CN¥1.47 Billion | CN¥334.85 Million | ▼ -5.7 pp |
| 2022 | 34.0% | CN¥1.28 Billion | CN¥3.76 Billion | CN¥1.57 Billion | CN¥295.96 Million | ▼ -33.8 pp |
| 2021 | 67.8% | CN¥2.06 Billion | CN¥3.04 Billion | CN¥2.25 Billion | CN¥190.68 Million | ▼ -9.1 pp |
| 2020 | 76.9% | CN¥1.98 Billion | CN¥2.58 Billion | CN¥2.22 Billion | CN¥237.55 Million | ▼ -1.9 pp |
| 2019 | 78.8% | CN¥2.02 Billion | CN¥2.57 Billion | CN¥2.26 Billion | CN¥240.02 Million | ▲ +1.3 pp |
| 2018 | 77.4% | CN¥1.92 Billion | CN¥2.49 Billion | CN¥2.16 Billion | CN¥235.15 Million | ▲ +0.4 pp |
| 2017 | 77.0% | CN¥1.82 Billion | CN¥2.37 Billion | CN¥2.10 Billion | CN¥279.47 Million | ▲ +2.7 pp |
| 2016 | 74.4% | CN¥1.64 Billion | CN¥2.20 Billion | CN¥1.92 Billion | CN¥286.57 Million | ▼ -2.5 pp |
| 2015 | 76.9% | CN¥1.54 Billion | CN¥2.01 Billion | CN¥1.92 Billion | CN¥375.76 Million | ▼ -3.1 pp |
| 2014 | 80.0% | CN¥1.51 Billion | CN¥1.88 Billion | CN¥1.72 Billion | CN¥211.02 Million | ▲ +0.9 pp |
| 2013 | 79.1% | CN¥1.27 Billion | CN¥1.61 Billion | CN¥1.41 Billion | CN¥142.20 Million | ▼ -4.6 pp |
| 2012 | 83.7% | CN¥1.19 Billion | CN¥1.42 Billion | CN¥1.31 Billion | CN¥118.75 Million | ▲ +1.6 pp |
| 2011 | 82.1% | CN¥1.10 Billion | CN¥1.33 Billion | CN¥1.20 Billion | CN¥103.36 Million | ▼ -1.5 pp |
| 2010 | 83.6% | CN¥1.03 Billion | CN¥1.24 Billion | CN¥1.15 Billion | CN¥118.57 Million | ▼ -4.4 pp |
| 2009 | 88.0% | CN¥1.01 Billion | CN¥1.15 Billion | CN¥1.19 Billion | CN¥186.20 Million | ▲ +19.7 pp |
| 2008 | 68.3% | CN¥86.71 Million | CN¥126.92 Million | CN¥189.66 Million | CN¥102.95 Million | ▲ +12.3 pp |
| 2007 | 56.0% | CN¥43.12 Million | CN¥76.96 Million | CN¥127.77 Million | CN¥84.64 Million | ▲ +43.1 pp |
| 2006 | 12.9% | CN¥4.81 Million | CN¥37.24 Million | CN¥76.61 Million | CN¥71.80 Million | — |